AI Article Synopsis
Article Abstract
Background: Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and severe manifestation of anti-MDA5 dermatomyositis (MDA5-DM) associated with poor outcome. The optimal treatment regimen for MDA5-DM RP-ILD is yet to be determined. Specifically, the value of adding plasma exchange (PLEX) to corticosteroids and immunosuppressants remains unclear. We aimed to evaluate the effect of PLEX on the outcome of patients with MDA5-DM RP-ILD.
Methods: This French nationwide multicentre retrospective study included all MDA5-DM RP-ILD patients from 2012 to 2021 admitted to 18 centres. The primary endpoint was one-year transplant-free survival.
Results: 51 patients with MDA5-DM RP-ILD (female 67%; mean age at disease onset: 51 ± 11.6 years) were included. Thirty-two (63%) patients required mechanical ventilation and twenty-five (49%) received PLEX. One-year mortality or lung transplant occurred in 63% cases after a median follow-up of 77 [38-264] days. The Cox proportional hazards multivariable model only retained mechanical ventilation but not PLEX (p = 0.7) as independent predictor of the primary endpoint. One-year transplant-free survival rates in PLEX + vs. PLEX-were 20% vs. 54% (p = 0.01), respectively. The Kaplan-Meier estimated probabilities of one-year transplant-free survival was statistically higher in PLEX-compared to PLEX + patients (p = 0.05). PLEX + compared to PLEX-patients more frequently received mechanical ventilation and immunosuppressants suggesting PLEX + patients had a more severe disease.
Conclusion: MDA5-DM RP-ILD is associated with poor rate of one-year transplant-free survival. The use of PLEX was not associated with a better outcome albeit they were mainly given to more severe patients. While our study reports the largest series of MDA5-DM RP-ILD given PLEX, these results needs to be interpreted with caution owing the numerous selection, indication and interpretation bias. Further studies are needed to evaluate their efficacy in this setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaut.2022.102941 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis.
Clin Rheumatol
January 2025
Division of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Introduction: Anti-MDA5-positive dermatomyositis (anti-MDA5-DM) is a rare autoimmune disease that often leads to rapid-progressive interstitial lung disease (RP-ILD). The lack of effective prediction and treatment methods makes RP-ILD a major risk factor for death in patients with this condition. S100A6 is a member of the S100 Ca2 + - binding protein family, which plays important roles in inflammation, tumor, injury, and fibroblast reparation.
View Article and Find Full Text PDFDysregulated CD38 expression on T cells was associated with rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 positive dermatomyositis.
Front Immunol
November 2024
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Background: Anti-melanoma differentiation-associated gene 5 positive dermatomyositis (MDA5+ DM) is a life-threatening disease due to rapidly progressive interstitial lung disease (RP-ILD). We aimed to investigate the expression profile of T cell subsets in MDA5+ DM patients, seeking for possible disease-causing T cell subsets and potential biomarkers to distinguish ILD, especially RP-ILD patients.
Methods: Peripheral blood T cell subpopulations were immunophenotyped in 24 MDA5+ DM patients and 21 healthy controls (HCs) by flow cytometry.
Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study.
Clin Exp Rheumatol
September 2024
Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Article Synopsis
- The study investigates the effectiveness and safety of a triple-combination therapy (high-dose corticosteroids, tacrolimus, and intravenous cyclophosphamide) for patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) who have interstitial lung disease (ILD).
- Despite hopes for positive outcomes, the therapy did not improve patient prognosis and was associated with higher mortality, particularly in high-risk patients with rapidly progressive ILD (RP-ILD).
- The findings indicate that this treatment may not be beneficial for MDA5+ DM patients, highlighting the need for further research to find safer and more effective therapies for this condition.
Successful treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease complicated by bilateral breast cancer following the additional tofacitinib: A case report.
Mod Rheumatol Case Rep
January 2025
Department of Rheumatology, Kakogawa Central City Hospital, Kakogawa, Hyogo, Japan.
Article Synopsis
- MDA-5 antibody-positive dermatomyositis (MDA5-DM) often leads to rapidly progressive interstitial lung disease (RP-ILD) and can be complicated by cancer, though such instances are rare compared to other forms of dermatomyositis.
- Traditional treatment involves addressing cancer first, but surgeries and chemotherapies can be risky due to respiratory issues.
- A case study of a 48-year-old woman with MDA5-DM and bilateral breast cancer showed improvement with tofacitinib and plasma exchange therapy, ultimately allowing her to undergo surgery; she has remained cancer-free and symptom-free for three years since treatment.
Anti-melanoma differentiation-associated gene 5 (anti-MDA5) dermatomyositis (DM) is a subset of amyopathic myositis and is associated with unique cutaneous manifestations and rapidly progressive interstitial lung disease (RP-ILD). A rare complication associated with high mortality is the occurrence of pneumomediastinum. We present a case of a 58-year-old female with anti-MDA5 DM-associated interstitial lung disease (ILD) complicated by pneumomediastinum.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!